Detalhe da pesquisa
1.
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
Blood
; 141(13): 1584-1596, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375120
2.
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Blood
; 136(1): 93-105, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32202637
3.
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Blood
; 132(5): 521-532, 2018 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29743179
4.
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Blood
; 131(21): 2357-2366, 2018 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29483101
5.
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
Blood
; 129(11): 1469-1479, 2017 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28049639
6.
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
Blood
; 128(1): 82-92, 2016 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27127301
7.
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.
Blood
; 126(19): 2213-9, 2015 11 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26337493
8.
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.
Blood
; 123(21): 3286-95, 2014 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24659631
9.
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Lancet Oncol
; 16(2): 169-76, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25555420
10.
The future of kinase inhibitors for DLBCL?
Blood
; 131(21): 2278-2280, 2018 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29794076
11.
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
Blood
; 122(14): 2412-24, 2013 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-23940282
12.
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
Blood
; 121(1): 136-47, 2013 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-23165478
13.
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
Haematologica
; 100(12): 1571-8, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26430171
14.
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
Blood
; 120(6): 1262-73, 2012 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-22740450
15.
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.
Blood
; 117(16): 4323-7, 2011 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-21378270
16.
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Blood
; 117(23): 6287-96, 2011 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-21422473
17.
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
Blood
; 117(2): 591-4, 2011 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-20959606
18.
Whole exome sequencing in families with CLL detects a variant in Integrin ß 2 associated with disease susceptibility.
Blood
; 128(18): 2261-2263, 2016 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27629550
19.
The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia.
Blood Adv
; 7(1): 145-158, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35358998
20.
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Blood
; 116(12): 2078-88, 2010 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-20522708